Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited Fundamental Analysis
Acotec Scientific Holdings Limited (6669.HK) shows moderate financial fundamentals with a PE ratio of 36.80, profit margin of 20.07%, and ROE of 6.71%. The company generates $0.5B in annual revenue with strong year-over-year growth of 12.69%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 6669.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6669.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate6669.HK shows balanced valuation metrics.
Growth Score
Moderate6669.HK shows steady but slowing expansion.
Financial Health Score
Excellent6669.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate6669.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 6669.HK Expensive or Cheap?
P/E Ratio
6669.HK trades at 36.80 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 6669.HK's PEG of 1.36 indicates fair valuation.
Price to Book
The market values Acotec Scientific Holdings Limited at 2.42 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 48.75 times EBITDA. This signals the market has high growth expectations.
How Well Does 6669.HK Make Money?
Net Profit Margin
For every $100 in sales, Acotec Scientific Holdings Limited keeps $20.07 as profit after all expenses.
Operating Margin
Core operations generate 22.01 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.71 in profit for every $100 of shareholder equity.
ROA
Acotec Scientific Holdings Limited generates $5.18 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Acotec Scientific Holdings Limited generates strong operating cash flow of $164.73M, reflecting robust business health.
Free Cash Flow
Acotec Scientific Holdings Limited generates strong free cash flow of $141.55M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.47 in free cash annually.
FCF Yield
6669.HK converts 4.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
36.80
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.36
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.23
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.16
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.19
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How 6669.HK Stacks Against Its Sector Peers
| Metric | 6669.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 36.80 | 28.54 | Worse (Expensive) |
| ROE | 6.71% | 738.00% | Weak |
| Net Margin | 20.07% | -43982.00% (disorted) | Strong |
| Debt/Equity | 0.16 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 6.19 | 2806.01 | Strong Liquidity |
| ROA | 5.18% | -14624.00% (disorted) | Weak |
6669.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Acotec Scientific Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
344.98%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
135.52%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
438.85%
Industry Style: Defensive, Growth, Innovation
High Growth